Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
PSMA-RLT in Patients with Metastatic Hormone-Sensitive Prostate Cancer: A Retrospective Study.
Banda A, Privé BM, Allach Y, Uijen MJM, Peters SMB, Loeff CC, Gotthardt M, Muselaers CHJ, Witjes JA, van Oort IM, Sedelaar JPM, Westdorp H, Mehra N, Khreish F, Ezziddin S, Sabet A, Kreissl MC, Winkens T, Seifert P, Janssen MJR, van Gemert WAM, Nagarajah J. Banda A, et al. Among authors: peters smb. Cancers (Basel). 2022 Dec 31;15(1):297. doi: 10.3390/cancers15010297. Cancers (Basel). 2022. PMID: 36612293 Free PMC article.
Lutetium-177-PSMA-617 in Low-Volume Hormone-Sensitive Metastatic Prostate Cancer: A Prospective Pilot Study.
Privé BM, Peters SMB, Muselaers CHJ, van Oort IM, Janssen MJR, Sedelaar JPM, Konijnenberg MW, Zámecnik P, Uijen MJM, Schilham MGM, Eek A, Scheenen TWJ, Verzijlbergen JF, Gerritsen WR, Mehra N, Kerkmeijer LGW, Smeenk RJ, Somford DM, van Basten JA, Heskamp S, Barentsz JO, Gotthardt M, Witjes JA, Nagarajah J. Privé BM, et al. Among authors: peters smb. Clin Cancer Res. 2021 Jul 1;27(13):3595-3601. doi: 10.1158/1078-0432.CCR-20-4298. Epub 2021 Apr 21. Clin Cancer Res. 2021. PMID: 33883176
Intra-therapeutic dosimetry of [177Lu]Lu-PSMA-617 in low-volume hormone-sensitive metastatic prostate cancer patients and correlation with treatment outcome.
Peters SMB, Privé BM, de Bakker M, de Lange F, Jentzen W, Eek A, Muselaers CHJ, Mehra N, Witjes JA, Gotthardt M, Nagarajah J, Konijnenberg MW. Peters SMB, et al. Eur J Nucl Med Mol Imaging. 2022 Jan;49(2):460-469. doi: 10.1007/s00259-021-05471-4. Epub 2021 Jul 4. Eur J Nucl Med Mol Imaging. 2022. PMID: 34218300 Free PMC article.
[68Ga]Ga-PSMA-11 PET imaging as a predictor for absorbed doses in organs at risk and small lesions in [177Lu]Lu-PSMA-617 treatment.
Peters SMB, Hofferber R, Privé BM, de Bakker M, Gotthardt M, Janssen M, de Lange F, Muselaers CHJ, Mehra N, Witjes JA, Costa PF, Nagarajah J, Konijnenberg MW, Jentzen W. Peters SMB, et al. Eur J Nucl Med Mol Imaging. 2022 Mar;49(4):1101-1112. doi: 10.1007/s00259-021-05538-2. Epub 2021 Oct 8. Eur J Nucl Med Mol Imaging. 2022. PMID: 34623453 Free PMC article.
89Zr-labeled PSMA ligands for pharmacokinetic PET imaging and dosimetry of PSMA-617 and PSMA-I&T: a preclinical evaluation and first in man.
Privé BM, Derks YHW, Rosar F, Franssen GM, Peters SMB, Khreish F, Bartholomä M, Maus S, Gotthardt M, Laverman P, Konijnenberg MW, Ezziddin S, Nagarajah J, Heskamp S. Privé BM, et al. Among authors: peters smb. Eur J Nucl Med Mol Imaging. 2022 May;49(6):2064-2076. doi: 10.1007/s00259-021-05661-0. Epub 2021 Dec 21. Eur J Nucl Med Mol Imaging. 2022. PMID: 34932154
Thoughts on "Tumor Sink Effect in 68Ga-PSMA-11 PET: Myth or Reality?".
Privé BM, Peters SMB, Uijen MJM, Janssen MJR, van Gemert WAM, Kreissl MC, Ezzidin S, Konijnenberg MW, Nagarajah J. Privé BM, et al. Among authors: peters smb. J Nucl Med. 2022 Jul;63(7):1124-1125. doi: 10.2967/jnumed.122.263802. Epub 2022 Jan 13. J Nucl Med. 2022. PMID: 35027370 Free article. No abstract available.
27 results